868046-19-9|Elsulfavirine|Elsulfavirine|No data available-范德生物科技公司

Elsulfavirine

NMR下载 COA and HPLC MSDS下载
names：
Elsulfavirine
CAS号：
868046-19-9
MDL Number： No data available
MF(分子式)： C24H17BrCl2FN3O5S MW(分子量)： 629.28
EINECS:No data available Reaxys Number:No data available
Pubchem ID:11527519 Brand:BIOFOUNT

(868046-19-9)Elsulfavirine是HIV-1感染的逆转录酶的抑制剂,也是一种有效的抗 HIV 的新型药物.

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000674-250mg	250mg	>97%	¥ 0.00	¥ 0.00		Backorder	- +	¥ 0.00
YZM000674-100mg	100mg	>97%	¥ 0.00	¥ 0.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Elsulfavirine(868046-19-9);
英文别名	Elsulfavirine(868046-19-9);Elpida;2-[4-bromo-3-(3-chloro-5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro-4-propionylsulfamoyl-phenyl)-acetamide;
CAS号	868046-19-9
SMILES	O=C(NC1=CC=C(S(=O)(NC(CC)=O)=O)C=C1Cl)CC2=CC=C(Br)C(OC3=CC(C#N)=CC(Cl)=C3)=C2F
Inchi	InChI = 1S / C24H17BrCl2FN3O5S / c1-2-21（32）31-37（34,35）17-4-6-20（19（27）11-17）30-22（33）9-14-3- 5-18（25）24（23（14）28）36-16-8-13（12-29）7-15（26）10-16 / h3-8,10-11H，2,9H2,1H3，（H，30,33）（H，31,32）
InchiKey	ULTDEARCBRNRGR-UHFFFAOYSA-N
分子式 Formula	C24H17BrCl2FN3O5S
分子量 Molecular Weight	629.28
闪点 FP	No data available
熔点 Melting point	No data available
沸点 Boiling point	No data available
Polarizability极化度	No data available
密度 Density	1.7±0.1克/厘米3
蒸汽压 Vapor Pressure	No data available
溶解度Solubility
性状	Solid
储藏条件 Storage conditions	请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.

Elsulfavirine(868046-19-9)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags；Elsulfavirine试剂,Elsulfavirine杂质,Elsulfavirine中间体,Elsulfavirine密度,Elsulfavirine溶解度,Elsulfavirine旋光度,Elsulfavirine合成,Elsulfavirine闪点,Elsulfavirine熔点,Elsulfavirine结构式,Elsulfavirine购买,

产品说明	(868046-19-9)Elsulfavirine 是HIV-1感染的逆转录酶的抑制剂,也是一种有效的抗 HIV 的新型药物.
Introduction	Elsulfavirine(868046-19-9) is a reverse transcriptase inhibitors forHIVinfection and is a new antiIV drug.
Application1
Application2
Application3

Elsulfavirine(868046-19-9)药理学：

(868046-19-9)Elsulfavirine 是HIV-1感染的逆转录酶的抑制剂,也是一种有效的抗 HIV 的新型药物.

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Elsulfavirine: First Global Approval PMID 28940154; Drugs 2017 Oct; 77(16):1811-1816 (Review Article) Name matches: nucleoside elsulfavirine

Emerging reverse transcriptase inhibitors for HIV-1 infection PMID 29737220; Expert opinion on emerging drugs 2018 06; 23(2):149-157 (Review Article) Name matches: nucleoside elsulfavirine

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment PMID 31556749; Expert opinion on drug metabolism & toxicology 2019 Oct; 15(10):813-829 (Review Article

Emerging reverse transcriptase inhibitors for HIV-1 infection PMID 29737220; Expert opinion on emerging drugs 2018 06; 23(2):149-157 (Review Article) Name matches: hiv-1 infection elsulfavirine

Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors PMID 30417402; Medicinal research reviews 2019 07; 39(4):1235-1273 (Re

Elsulfavirine(868046-19-9)参考文献：

1、Novel Antiretroviral Agents Mary C. Cambou & Raphael J. Landovitz

Abstract：Purpose of Review Combination antiretroviral therapy (cART) has had dramatic effects on morbidity and mortality for persons living with HIV (PLWH). Despite significant progress in treatment efficacy, tolerability, and reducing pill burden, new agents are needed to address issues of resistance, drug-drug interactions, end organ disease, and adherence. This review covers novel ART agents recently approved or in development. Recent Findings Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials. While previous maturation inhibitors (MI) were hampered by issues of drug resistance, a recent phase IIa trial for a second-generation MI demonstrated promising antiviral activity. A phase I trial to evaluate a transdermal implant of islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), maintained concentrations above the target pharmacokinetic threshold at 12 weeks. The attachment inhibitor fostemsavir is available in the USA for compassionate use in multi-drug-resistant (MDR) HIV. Summary New antiretroviral agents show promise for both extended-duration dosing and MDR HIV.

2、Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors
Francesca Marino-Merlo, Beatrice Macchi, Daniele Armenia, Maria Concetta Bellocchi, Francesca Ceccherini-Silberstein, Antonio Mastino & Sandro Grelli???????

Abstract：The biology of HIV is rather complex due to high rate of replication, frequent recombination, and introduction of mutations. This gives rise to a number of distinct variants referred as quasispecies. In addition, the latency within reservoir allows the periodic reactivation of virus replication. The rapid replication of HIV allows immune response escape and establishment of resistance to therapy that can be acquired through drug selection and/or transmitted among individuals. This prompted, over the years, the development of a range of assays aimed to determine drug resistance and sensitivity, to be used both in clinical practice and in antiviral research. Reverse transcriptase (RT) inhibitors have an eminent place among the anti-HIV drugs, being constantly present from the beginning until today in the most commonly used antiviral regimens. This mini-review seeks to provide an up-to-date overview of recent efforts in developing even more reliable and simple methods, of both genotypic and phenotypic types, for specifically detecting drug resistance and sensitivity to RT inhibitors.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开